Fermenta Biotech Peer Comparison
NSE: FERMENTA | BSE: 506414
₹446.15
As on 20-Nov-2026IST
Market cap
₹1,312 Cr
Revenue (TTM)
₹513 Cr
P/E Ratio
25.5
P/B Ratio
3.1
Div. Yield
0.8 %
| Fermenta Biotech | Eris Lifesciences | Pfizer | Shilpa Medicare | Caplin Point Lab | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
1,312 | 18,307 | 17,610 | 16,634 | 15,421 |
Revenue (₹ Cr) |
513 | 3,330 | 2,654 | 1,842 | 2,383 |
Net Profit (₹ Cr) |
49.59 | 720.77 | 859.38 | 308.62 | 700.18 |
Net Margin (%) |
9.37 | 21.60 | 30.42 | 16.63 | 27.87 |
RoE (%) |
11.24 | 18.93 | 18.58 | 11.81 | 18.40 |
Price to Earnings |
25.55 | 25.87 | 20.49 | 50.04 | 22.38 |
Price-To-Book |
3.14 | 4.42 | 4.02 | 6.03 | 3.95 |
Income Statement (₹ Cr)
| Fermenta Biotech | Eris Lifesciences | Pfizer | Shilpa Medicare | Caplin Point Lab | |
|---|---|---|---|---|---|
|
Operating Revenue
|
513.44 | 3,329.63 | 2,654.29 | 1,841.62 | 2,383.13 |
|
Total Income
|
529.08 | 3,337.47 | 2,825.39 | 1,855.87 | 2,512.01 |
|
Total Expenditure
|
430.32 | 2,168.88 | 1,681.39 | 1,328.95 | 1,552.50 |
|
EBITDA
|
83.12 | 1,160.75 | 972.90 | 512.67 | 830.63 |
|
Depreciation
|
20.88 | 285.40 | 57.71 | 130.47 | 83.19 |
|
EBIT
|
62.24 | 875.35 | 915.19 | 382.20 | 747.44 |
|
Interest
|
12.13 | 187.51 | 8.91 | 49.12 | 0.94 |
|
Other Income
|
15.64 | 7.84 | 171.10 | 14.25 | 128.88 |
|
Exceptional Items
|
6.88 | -53.14 | 82.90 | 11.73 | 0.00 |
|
Profit before Tax
|
72.63 | 642.54 | 1,160.28 | 359.06 | 875.38 |
|
Provision for Tax
|
23.04 | -78.23 | 300.90 | 50.44 | 175.20 |
|
Profit after Tax
|
49.59 | 720.77 | 859.38 | 308.62 | 700.18 |
Liabilities (₹ Cr)
| Fermenta Biotech | Eris Lifesciences | Pfizer | Shilpa Medicare | Caplin Point Lab | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
418.12 | 4,144.34 | 4,385.41 | 2,757.68 | 3,902.45 |
|
Minority Interest
|
1.79 | -10.85 | 0.00 | 0.00 | -11.18 |
|
Non-Current Liabilities
|
33.18 | 758.48 | 222.21 | 363.37 | 55.61 |
|
Current Liabilities
|
250.39 | 2,681.14 | 685.36 | 1,016.50 | 366.06 |
|
Total Liabilities
|
647.94 | 7,246.72 | 4,921.88 | 3,705.61 | 4,037.51 |
Assets (₹ Cr)
| Fermenta Biotech | Eris Lifesciences | Pfizer | Shilpa Medicare | Caplin Point Lab | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
253.89 | 5,578.78 | 905.21 | 2,763.86 | 1,528.69 |
|
Current Assets
|
423.38 | 1,800.86 | 4,024.56 | 1,277.15 | 2,696.84 |
|
Total Assets
|
647.94 | 7,246.72 | 4,921.88 | 3,705.61 | 4,037.51 |
|
Total Debt*
|
108.89 | 2,309.68 | 2.50 | 657.97 | 0.57 |
|
Net Current Assets
|
173.00 | -880.28 | 3,339.20 | 260.65 | 2,330.78 |
|
Contingent Liabilities
|
1.63 | 51.57 | 370.49 | 160.01 | 17.53 |
Cashflow (₹ Cr)
| Fermenta Biotech | Eris Lifesciences | Pfizer | Shilpa Medicare | Caplin Point Lab | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
92.83 | 537.99 | 967.57 | 342.18 | 523.24 |
|
Cash Flow from Investing Activities
|
-43.00 | -369.46 | -561.67 | -325.92 | -582.30 |
|
Cash from Financing Activities
|
-42.29 | -313.53 | -798.31 | 13.62 | -46.46 |
|
Net Cash Inflow / Outflow
|
7.55 | -145.00 | -392.41 | 29.88 | -105.52 |
Ratios
Profitability Ratios
| Fermenta Biotech | Eris Lifesciences | Pfizer | Shilpa Medicare | Caplin Point Lab | |
|---|---|---|---|---|---|
|
ROCE (%)
|
21.99 | 14.47 | 23.39 | 11.43 | 24.97 |
|
ROE (%)
|
11.24 | 18.93 | 18.58 | 11.81 | 18.40 |
|
ROA (%)
|
7.36 | 9.78 | 17.36 | 8.09 | 17.77 |
|
EBIT Margin (%)
|
12.12 | 26.29 | 34.48 | 20.75 | 31.36 |
|
Net Margin (%)
|
9.37 | 21.60 | 30.42 | 16.63 | 27.87 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Fermenta Biotech | Eris Lifesciences | Pfizer | Shilpa Medicare | Caplin Point Lab | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-8.77 | 11.06 | 11.75 | 37.26 | 16.84 |
|
EBIT Growth (%)
|
-48.95 | 13.71 | 21.45 | 56.89 | 18.76 |
|
Net Profit Growth (%)
|
-55.26 | 60.98 | 2.39 | 127.86 | 17.44 |
|
EPS Growth (%)
|
-58.64 | 80.38 | 13.17 | 5.65 | 17.02 |
|
Book Value Growth (%)
|
11.21 | 36.71 | -0.34 | 9.67 | 26.75 |
Valuation Ratios
| Fermenta Biotech | Eris Lifesciences | Pfizer | Shilpa Medicare | Caplin Point Lab | |
|---|---|---|---|---|---|
|
Price / Earnings
|
28.33 | 23.96 | 22.07 | 52.69 | 22.38 |
|
Price / Book Value
|
3.14 | 4.42 | 4.02 | 6.03 | 3.95 |
|
Dividend Yield (%)
|
0.84 | 0.00 | 1.95 | 0.07 | 0.39 |
|
EV/EBITDA
|
16.60 | 17.70 | 14.91 | 33.64 | 17.35 |
|
Market Cap (₹ Cr)
|
914.72 | 17,980.08 | 21,592.90 | 6,819.66 | 11,439.22 |
Solvency Ratios
| Fermenta Biotech | Eris Lifesciences | Pfizer | Shilpa Medicare | Caplin Point Lab | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.01 | 0.10 | 0.00 | 0.08 | 0.00 |
|
Short term debt to equity ratio
|
0.23 | 0.12 | 0.00 | 0.16 | 0.00 |
|
Current Ratio
|
1.69 | 0.67 | 5.87 | 1.26 | 7.37 |
|
Quick Ratio
|
1.02 | 0.49 | 5.23 | 0.82 | 5.88 |
|
Interest Coverage
|
6.99 | 4.43 | 131.22 | 8.31 | 932.26 |
Operating Efficiency Ratios
| Fermenta Biotech | Eris Lifesciences | Pfizer | Shilpa Medicare | Caplin Point Lab | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
23.39 | 18.98 | 9.10 | 29.09 | 37.32 |
|
Asset Turnover
|
0.76 | 0.45 | 0.54 | 0.48 | 0.60 |
|
Receivable days
|
71.83 | 63.88 | 26.06 | 113.81 | 121.68 |
|
Inventory Days
|
95.93 | 43.27 | 65.95 | 84.76 | 63.83 |
|
Payable days
|
147.04 | 151.85 | 81.01 | 101.94 | 108.28 |
|
Cash Conversion Cycle
|
20.73 | -44.70 | 11.00 | 96.62 | 77.23 |